SLGT2-Inhibitors Decrease Risk for MACEs in Patients With Type 2 Diabetes Endocrinology Advisor, 04 May 2023 Sodium-glucose cotransporter 2- (SGLT2-) inhibitor therapy reduces atherosclerotic plaque progression, leading to favorable…